Genetic defects in von Willebrand disease type 3 in Indian and Greek patients

P K Gupta1, R Saxena, E Adamtziki

  • 1Department of Transfusion Medicine, Haematology Section, Armed Forces Medical College, Pune-411040, India. paw_5671@hotmail.com

Insights

Von Willebrand disease type 3 is a severe bleeding disorder caused by diverse mutations in the VWF gene. Gene conversions and R1659X mutations are the most frequent molecular defects identified in Indian and Greek patients.

Area of Science:

  • Genetics
  • Hematology
  • Molecular Biology

Background:

  • Von Willebrand disease (VWD) type 3 is a severe, autosomal recessive bleeding disorder.
  • It presents with a consistent phenotype but diverse underlying genetic causes.
  • Understanding the molecular basis is crucial for diagnosis and management.

Purpose of the Study:

  • To investigate the molecular basis of VWD type 3 in Indian and Greek populations.
  • To identify specific mutations in the von Willebrand factor (VWF) gene.
  • To correlate genotype with the severe VWD type 3 phenotype.

Main Methods:

  • Screening of the complete VWF gene in 21 Indian and 6 Greek patients with VWD type 3.
  • Utilizing Polymerase Chain Reaction (PCR) and direct sequencing of VWF exons and flanking introns.
  • Analysis focused on identifying mutations and characterizing their nature (e.g., nonsense, deletions, insertions, gene conversions).

Main Results:

  • VWD type 3 diagnosis confirmed by detecting null alleles or two mutations in 22 patients.
  • Most identified defects resulted in null alleles (16 out of 23 patients).
  • Common mutations included homozygous nonsense mutations (R1659X, W553X, L1267X) and gene conversions, particularly R1659X in exon 28.

Conclusions:

  • VWD type 3 arises from a wide spectrum of mutations across the VWF gene.
  • The majority of mutations (16/23) lead to null alleles, consistent with the severe phenotype.
  • Gene conversions and the R1659X mutation were identified as the most prevalent molecular defects in this cohort.
Abstract

Related Concept Videos

Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Incomplete Dominance01:43

Incomplete Dominance

Gregor Mendel's work (1822 - 1884) was primarily focused on pea plants. Through his initial experiments, he determined that every gene in a diploid cell has two variants called alleles inherited from each parent. He suggested that amongst these two alleles, one allele is dominant in character and the other recessive. The combination of alleles determines the phenotype of a gene in an organism.
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pedigree Analysis01:35

Pedigree Analysis

Overview